European Markets Experience Growth for Oxygen Therapy Devices

The rising incidence of chronic obstructive pulmonary disease (COPD) is resulting in an increase in the number of people requiring oxygen therapy treatment, thereby leading to growth in the European oxygen therapy devices market.

These are the latest findings from Frost & Sullivan (Palo Alto, CA, USA), an international consulting firm. Moreover, with increasing pressure to reduce healthcare expenditure, the home care segment has been given preference and has become a huge revenue generator for the oxygen therapy devices markets. Improvements in the reimbursement system and development of a well-established network of distributors to provide service for the growing home care market are other favorable factors that are influencing market growth.

The markets have grown due to the use of increasingly sophisticated portable devices, causing a shift the traditional use of oxygen stored in large-sized cylinders. This has added value to manufacturers existing product line. The development of new products to cater to all sections of the COPD population has helped the market grow steadily.

"There has been a steady increase in the incidence of COPD in the last decade, which has resulted in greater need for supplementary oxygen,” said Frost & Sullivan research analyst Sowmya Rajagopalan. "Moreover, there have been several promotional programs to increase awareness of COPD and showcase the differences between COPD and asthma, which have enabled quick and accurate diagnosis of COPD.”

Frost & Sullivan found that the European markets for oxygen therapy devices earned revenues of US$232.7 million in 2006 and estimates this to reach $354.5 million in 2013.


Related Links:
Frost & Sullivan